Ten-year outcome of Eculizumab in kidney transplant recipients with atypical hemolytic uremic syndrome- a single center experience

Keyphrases

• 10-year Outcomes 100%
• Acute Kidney Injury 16%
• Atypical Hemolytic Uremic Syndrome (aHUS) 100%
• Clinical Data 16%
• Clinical Diagnosis 16%
• Complement Factors 16%
• Eculizumab 100%
• Encapsulated Organisms 16%
• Estimated Glomerular Filtration Rate 16%
• Etiology 16%
• Favorable Outcome 16%
• Follow-up Data 33%
• Genetic Testing 16%
• Infectious Complications 16%
• Kidney Disease 16%
• Kidney Transplant 33%
• Kidney Transplant Recipients 100%
• Living Donor 16%
• Native Kidney 16%
• Nineteen 16%
• Patient Selection 16%
• Prophylactic Use 16%
• Response to Therapy 16%
• Retrospective Analysis 16%
• Single-center Experience 100%
• Therapeutic Use 16%
• Thrombotic Microangiopathy 33%
• Transplantation 16%
• Transplanted Kidney 16%

Medicine and Dentistry

• Acute Kidney Injury 16%
• Atypical Hemolytic Uremic Syndrome 100%
• Complement Factor 16%
• Disease 16%
• Eculizumab 100%
• Epileptic Absence 16%
• Genetic Screening 16%
• Glomerular Filtration Rate 16%
• Infectious Complication 16%
• Kidney Graft 100%
• Microangiopathy 33%
• Patient History of Kidney Transplantation 16%
• Recurrent Disease 16%
• Secondary Infection 16%
• Severe Renal Impairment 16%
• Transplantation 66%